The impact of phosphate lowering agents on clinical and laboratory outcomes in chronic kidney disease patients: a systematic review and meta-analysis of randomized controlled trials
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Nephrology"
DOI: 10.1007/s40620-021-01065-3
Abstract: Besides reducing hyperphosphatemia in chronic kidney disease (CKD) patients, phosphate lowering agents might provide beneficial effects on clinical and laboratory parameters. This meta-analysis was conducted to comprehensively examine the impact of all phosphate lowering agents… read more here.
Keywords: lowering agents; phosphate lowering; clinical laboratory; meta analysis ... See more keywords
Pharmacological treatment with lipid-lowering agents after molecular identification of familial hypercholesterolemia: results from the Hipercol Brasil cohort.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of clinical lipidology"
DOI: 10.1016/j.jacl.2022.01.005
Abstract: BACKGROUND Familial hypercholesterolemia (FH) is an autosomal dominant disease characterized by the presence of high levels of total and low-density lipoprotein cholesterol (LDL-C). Statin treatment is recommended for all adults with FH. OBJECTIVE Here we… read more here.
Keywords: lipid lowering; lowering agents; treatment; cohort ... See more keywords
Contemporary choice of glucose lowering agents in heart failure patients with type 2 diabetes
Sign Up to like & getrecommendations! Published in 2019 at "Acta Cardiologica"
DOI: 10.1080/00015385.2019.1569313
Abstract: Abstract Background: The choice of glucose lowering agent in heart failure (HF)-patients can have a strong effect on HF-related adverse events, with some classes increasing and other classes reducing the risk. Little data is available… read more here.
Keywords: lowering agents; heart failure; choice glucose; type diabetes ... See more keywords
Design, synthesis, and biological activity of 9-O-cinnamoylberberines as novel lipid-lowering agents.
Sign Up to like & getrecommendations! Published in 2022 at "Natural product research"
DOI: 10.1080/14786419.2022.2085697
Abstract: Berberine possesses a wide spectrum of lipid regulation, and yet it has poor physicochemical property and cytotoxicity as a drug candidate. In order to alleviate the problems, a total of twenty-one 9-O-cinnamoylberberines and twenty 9-O-cinnamoyltetrahydroberberines… read more here.
Keywords: design synthesis; synthesis biological; lowering agents; biological activity ... See more keywords
Effects of glucose‐lowering agents on cardiovascular and renal outcomes in subjects with type 2 diabetes: An updated meta‐analysis of randomized controlled trials with external adjudication of events
Sign Up to like & getrecommendations! Published in 2022 at "Diabetes"
DOI: 10.1111/dom.14888
Abstract: To investigate the effects of glucose‐lowering agents on all‐cause mortality, and cardiovascular and renal outcomes in adults with type 2 diabetes. read more here.
Keywords: lowering agents; effects glucose; renal outcomes; glucose lowering ... See more keywords
THU0424 SHORT-TERM ADHERENCE OF URATE-LOWERING AGENTS WILL NOT IMPROVE END-STAGE RENAL DISEASE AND MORTALITY
Sign Up to like & getrecommendations! Published in 2020 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2020-eular.4008
Abstract: Background: Gout is the most common inflammatory arthritis worldwide with a diverse spectrum of clinical manifestations. Many studies indicated that gout is associated with hypertension, metabolic syndrome, chronic kidney disease and ischaemic heart diseases. Objectives:… read more here.
Keywords: lowering agents; stage renal; end stage; urate lowering ... See more keywords
Cardiovascular Effects of New Oral Glucose-Lowering Agents
Sign Up to like & getrecommendations! Published in 2018 at "Circulation Research"
DOI: 10.1161/circresaha.117.311588
Abstract: Cardiovascular disease (CVD) is a major challenge in the management of type 2 diabetes mellitus. Glucose-lowering agents that reduce the risk of major cardiovascular events would be considered a major advance, as recently reported with… read more here.
Keywords: outcome; lowering agents; type diabetes; diabetes mellitus ... See more keywords
Lipid-Lowering Agents.
Sign Up to like & getrecommendations! Published in 2019 at "Circulation Research"
DOI: 10.1161/circresaha.118.313171
Abstract: Several new or emerging drugs for dyslipidemia owe their existence, in part, to human genetic evidence, such as observations in families with rare genetic disorders or in Mendelian randomization studies. Much effort has been directed… read more here.
Keywords: lowering agents; lipid lowering; cholesterol;
Effects of Oral Glucose-Lowering Agents on Gut Microbiota and Microbial Metabolites
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Endocrinology"
DOI: 10.3389/fendo.2022.905171
Abstract: The current research and existing facts indicate that type 2 diabetes mellitus (T2DM) is characterized by gut microbiota dysbiosis and disturbed microbial metabolites. Oral glucose-lowering drugs are reported with pleiotropic beneficial effects, including not only… read more here.
Keywords: microbial metabolites; effects oral; gut microbiota; lowering agents ... See more keywords
Gynostemma pentaphyllum for dyslipidemia: A systematic review of randomized controlled trials
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2022.917521
Abstract: Objective: To evaluate the lipid-lowering effect and safety of Gynostemma pentaphyllum (GP) used alone or as adjunctive therapy for dyslipidemia. Methods: Eight databases and three clinical trial registries were searched until January 2022. Randomized controlled… read more here.
Keywords: lowering agents; mmol; gynostemma pentaphyllum; lipid lowering ... See more keywords